Melbourne, Aug 5, 2009 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its United States-based associate company Angioblast Systems Inc. has initiated a Phase 2 clinical trial to evaluate the safety and effectiveness of the company’s proprietary “off-the-shelf” adult stem cell product Revascor(TM) for improving heart muscle function in patients with the most severe, or class IV, end-stage form of heart failure.
